IV Fluids and Post-ERCP Pancreatitis

Condition(s) studied

Investigational drug(s) / intervention(s)

IV fluids: Amount of intravenous fluids delivered

Study summary

Aggressive intravenous hydration has been shown in randomized trials to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), though studied regimens are often impractical. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP. In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).

Eligibility

Primary outcome measure(s)

• post-ERCP pancreatitis — 30 days
  Number of participants with any 2 of: (1) epigastric abdominal pain, (2) serum amylase/lipase \>3x the upper limit of normal, (3) imaging findings consistent with acute pancreatitis

Trial sites (1)

More University of Calgary trials in Canada

Other trials for the same condition